Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
This is a diagnostic study. Patients were recruited from patients with clinically suspected or confirmed hepatocellular carcinoma and healthy volunteers were recruited for PET/or PET/CT imaging targeting a GPC3-specific probe (in the case of 68Ga-NOTA-aGPC3-scFv) , to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET CT imaging in patients with contraindications. General Information, clinical data, blood routine, liver and renal function, and other imaging data were collected. The final diagnosis was based on the histopathology of biopsy or surgical specimens.
• 1: Voluntarily participate and the person or their legal representative can sign an informed consent form
• 2: Adult patients (18 years of age or older), regardless of gender
• 3: Patients with newly diagnosed hepatocellular carcinoma with high clinical suspicion or confirmation (supporting evidence including imaging data and histopathologic examination, etc.) who agree to undergo histopathologic examination (if not performed prior to imaging) or/and 18F-FDG PET imaging
• 4: Healthy volunteer
• 5: Patients with a history of hepatocellular carcinoma, remission and recurrence after treatment
• 6: Willing and able to follow schedule visits, treatment plans and laboratory tests